Cargando…

Comment on “Disease exacerbation is common in inflammatory bowel disease patients treated with immune checkpoint inhibitors for malignancy”

We recently read with interest the original research article entitled "Disease exacerbation is common in inflammatory bowel disease patients treated with immune checkpoint inhibitors for malignancy". The abovementioned article is an observational retrospective cohort study, which could be...

Descripción completa

Detalles Bibliográficos
Autores principales: Argyriou, Konstantinos, Kotsakis, Athanasios
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Baishideng Publishing Group Inc 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9403700/
https://www.ncbi.nlm.nih.gov/pubmed/36159549
http://dx.doi.org/10.12998/wjcc.v10.i23.8425
_version_ 1784773437623894016
author Argyriou, Konstantinos
Kotsakis, Athanasios
author_facet Argyriou, Konstantinos
Kotsakis, Athanasios
author_sort Argyriou, Konstantinos
collection PubMed
description We recently read with interest the original research article entitled "Disease exacerbation is common in inflammatory bowel disease patients treated with immune checkpoint inhibitors for malignancy". The abovementioned article is an observational retrospective cohort study, which could be of particular value for clinicians to understand how immunotherapy affects pre-existing enteral disease in inflammatory bowel disease patients. Although we appreciate the endeavor of Samuel Rubin et al, based on our in-depth analysis, we detected a potential shortcoming in this article; thus, we present our comments in this letter. If the authors contemplate these comments on their relevant research, we believe that their contribution would be considerable for future studies.
format Online
Article
Text
id pubmed-9403700
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Baishideng Publishing Group Inc
record_format MEDLINE/PubMed
spelling pubmed-94037002022-09-23 Comment on “Disease exacerbation is common in inflammatory bowel disease patients treated with immune checkpoint inhibitors for malignancy” Argyriou, Konstantinos Kotsakis, Athanasios World J Clin Cases Letter to the Editor We recently read with interest the original research article entitled "Disease exacerbation is common in inflammatory bowel disease patients treated with immune checkpoint inhibitors for malignancy". The abovementioned article is an observational retrospective cohort study, which could be of particular value for clinicians to understand how immunotherapy affects pre-existing enteral disease in inflammatory bowel disease patients. Although we appreciate the endeavor of Samuel Rubin et al, based on our in-depth analysis, we detected a potential shortcoming in this article; thus, we present our comments in this letter. If the authors contemplate these comments on their relevant research, we believe that their contribution would be considerable for future studies. Baishideng Publishing Group Inc 2022-08-16 2022-08-16 /pmc/articles/PMC9403700/ /pubmed/36159549 http://dx.doi.org/10.12998/wjcc.v10.i23.8425 Text en ©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved. https://creativecommons.org/licenses/by-nc/4.0/This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
spellingShingle Letter to the Editor
Argyriou, Konstantinos
Kotsakis, Athanasios
Comment on “Disease exacerbation is common in inflammatory bowel disease patients treated with immune checkpoint inhibitors for malignancy”
title Comment on “Disease exacerbation is common in inflammatory bowel disease patients treated with immune checkpoint inhibitors for malignancy”
title_full Comment on “Disease exacerbation is common in inflammatory bowel disease patients treated with immune checkpoint inhibitors for malignancy”
title_fullStr Comment on “Disease exacerbation is common in inflammatory bowel disease patients treated with immune checkpoint inhibitors for malignancy”
title_full_unstemmed Comment on “Disease exacerbation is common in inflammatory bowel disease patients treated with immune checkpoint inhibitors for malignancy”
title_short Comment on “Disease exacerbation is common in inflammatory bowel disease patients treated with immune checkpoint inhibitors for malignancy”
title_sort comment on “disease exacerbation is common in inflammatory bowel disease patients treated with immune checkpoint inhibitors for malignancy”
topic Letter to the Editor
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9403700/
https://www.ncbi.nlm.nih.gov/pubmed/36159549
http://dx.doi.org/10.12998/wjcc.v10.i23.8425
work_keys_str_mv AT argyrioukonstantinos commentondiseaseexacerbationiscommonininflammatoryboweldiseasepatientstreatedwithimmunecheckpointinhibitorsformalignancy
AT kotsakisathanasios commentondiseaseexacerbationiscommonininflammatoryboweldiseasepatientstreatedwithimmunecheckpointinhibitorsformalignancy